Fulltext

Anacetrapib reduces progression of atherosclerosis, mainly by reducing non-HDL-cholesterol, improves lesion stability and adds to the beneficial effects of atorvastatin

Kühnast, Susan ; van der Tuin, Sam J.L. ; van der Hoorn, José W.A. ; van Klinken, Jan B. ; Simic, Branko ; Pieterman, Elsbet ; Havekes, Louis M. ; Landmesser, Ulf ; Lüscher, Thomas F. ; Willems van Dijk, Ko ; Rensen, Patrick C.N. ; Jukema, J. Wouter ; Princen, Hans M.G.

In: European Heart Journal, 2015, vol. 36, no. 1, p. 39-50

Aggiungi alla tua lista
    Titre
    • Anacetrapib reduces progression of atherosclerosis, mainly by reducing non-HDL-cholesterol, improves lesion stability and adds to the beneficial effects of atorvastatin
    Auteur
    • Kühnast, Susan. Gaubius Laboratory, TNO, Metabolic Health Research, Zernikedreef 9, 2333 CK, PO Box 2215, 2301 CE, Leiden, The Netherlands
    • van der Tuin, Sam J.L.. Einthoven Laboratory for Experimental Vascular Medicine, LUMC, Leiden, The Netherlands
    • van der Hoorn, José W.A.. Gaubius Laboratory, TNO, Metabolic Health Research, Zernikedreef 9, 2333 CK, PO Box 2215, 2301 CE, Leiden, The Netherlands
    • van Klinken, Jan B.. Einthoven Laboratory for Experimental Vascular Medicine, LUMC, Leiden, The Netherlands
    • Simic, Branko. Center for Molecular Cardiology, Campus Schlieren, University of Zurich, Zurich, Switzerland
    • Pieterman, Elsbet. Gaubius Laboratory, TNO, Metabolic Health Research, Zernikedreef 9, 2333 CK, PO Box 2215, 2301 CE, Leiden, The Netherlands
    • Havekes, Louis M.. Gaubius Laboratory, TNO, Metabolic Health Research, Zernikedreef 9, 2333 CK, PO Box 2215, 2301 CE, Leiden, The Netherlands
    • Landmesser, Ulf. University Heart Center, Department of Cardiology, University Hospital Zurich, Zurich, Switzerland
    • Lüscher, Thomas F.. University Heart Center, Department of Cardiology, University Hospital Zurich, Zurich, Switzerland
    • Willems van Dijk, Ko. Einthoven Laboratory for Experimental Vascular Medicine, LUMC, Leiden, The Netherlands
    • Rensen, Patrick C.N.. Einthoven Laboratory for Experimental Vascular Medicine, LUMC, Leiden, The Netherlands
    • Jukema, J. Wouter. Department of Cardiology, LUMC, Leiden, The Netherlands
    • Princen, Hans M.G.. Gaubius Laboratory, TNO, Metabolic Health Research, Zernikedreef 9, 2333 CK, PO Box 2215, 2301 CE, Leiden, The Netherlands
    Type de document
    • Postprint
    Langue
    • Inglese
    Publié dans
    • European Heart Journal, 2015, vol. 36, no. 1, p. 39-50. Oxford University Press
    Autre version électronique
    Identifiant OAI-PMH
    • oai:doc.rero.ch:300669
    Summary
    The present study is the first intervention study in a well-established, translational mouse model for hyperlipidaemia and atherosclerosis showing that anacetrapib dose-dependently reduces atherosclerosis development and adds to the anti-atherogenic effects of atorvastatin. This effect is mainly ascribed to the reduction in non-HDL-C despite a remarkable increase in HDL-C and without affecting HDL functionality. In addition, anacetrapib improves lesion stability